News Center
Research
Education
Patient Care
Give
About
Skin Cancers August 14, 2026
By Adam Hadhazy
The FDA finally gave the green light to bemotrizinol. We consulted three Stanford Medicine experts about why this is considered a massive leap forward for skin health in the U.S.
Contrary to the old adage, there is something new under the sun after all — at least here in the United States. For the first time in 27 years, the U.S. Food and Drug Administration has approved a new active sunscreen ingredient for over-the-counter use.
It’s a chemical called bemotrizinol (“beh-moh-TRIZ-in-ol”), also referred to as BEMT, and it offers major advantages over presently available U.S. sunscreens, according to three Stanford Medicine dermatologists.
Here’s what these experts on skin protection and ultraviolet radiation had to say about this new product, due to hit shelves in September.
Bemotrizinol was developed by Swiss chemists seeking better sunscreens in the 1990s. (Formula C38H49N3O5 for the chemistry geeks out there.).
It’s oil-soluble, meaning bemotrizinol would absorb into our oil-rich skin except for the fact that it is a big molecule. Instead, bemotrizinol is minimally absorbed through the skin and adheres well to our bodies, forming a layer that absorbs ultraviolet light from the sun and converts it to harmless heat.
From the pure standpoint of protecting our skin from the sun, bemotrizinol is a “gamechanger,” said Susan Swetter, MD, the Mosbacher Professor in Dermatology co-director of the Melanoma and Cutaneous Oncology Programs at Stanford Medicine and the Stanford Cancer Institute. “It’s the best broad spectrum ultraviolet radiation filter available.”  
Most sunscreens claim to offer broad spectrum coverage, meaning they absorb both kinds of ultraviolet light — dubbed UVA and UVB — that reach ground level and damage our skin. But available U.S. sunscreen filters do not cover the full spectrum of UVA, meaning a portion of this skin-penetrating light goes unchecked. “We have not had a good UVA filter on the U.S. market to date,” said Joyce Teng, MD, PhD, a professor of dermatology and director of Pediatric Dermatology at Stanford Children’s Health.
To be more specific:
Sunscreens historically available in the U.S. have provided UVA coverage only out to about 370 nanometers. Bemotrizinol covers the whole UVA spectrum, out to 400 nanometers. “Bemotrizinol is a huge step forward compared to so many other things we’ve had,” said Zakia Rahman, MD, a clinical professor of dermatology and director of the resident laser and aesthetic clinic at Stanford Medicine.
Chalk it up to different regulatory structures. Unlike most of the world, which treats sunscreen as an over-the-counter cosmetic, the U.S. has historically classified sunscreen as an over-the-counter drug. Accordingly, to be sold in American stores, sunscreens must go through strict regulatory approval for safety — including human testing — as well as efficacy and clear labeling. This is so consumers can easily understand how to safely administer the product themselves.
Those extra regulatory steps, plus bureaucratic rigamarole, held up ingredient approval for more than two decades. This involved legislation such as the Sunscreen Innovation Act from 2014 to create an official regulatory pathway for bemotrizinol review, and eventually the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 to modernize the over-the-counter drugs regulatory framework.
“I don’t want to say ‘battle,’ but it’s certainly been a greater-than-20-year effort to get superior ultraviolet filters incorporated into our sunscreens,” Swetter said.
No, quite the opposite, the Stanford Medicine experts said. “We have waited a really long time to have a new sunscreen option that’s better at UVA protection. On the plus side, there’s been added protection for consumers because of the testing process,” said Rahman, building on the safety history of bemotrizinol since its introduction in other countries circa 2000.
As part of its review, the FDA considered animal studies that showed no evidence for increased cancer risk or endocrine disruption, which is when substances interfere with natural hormonal systems, often manifesting as reproductive changes in parents or developmental issues in offspring.
Human testing of the 6% bemotrizinol concentration approved in the U.S. also found no signs of concerning skin irritation. Skin absorption, especially in pregnant women and children, was another significant concern, but testing ruled that out as well. “Since the bemotrizinol molecule is large, it does not cross the skin barrier easily, so that minimizes risk of systemic absorption,” Teng said. 
Overall, the FDA approved the chemical not only for sunscreens for adults but also children as young as six months. That could prove critical for bringing down skin cancer rates in subsequent generations.
“Bemotrizinol is tried and true and its FDA approval is great news for consumers,” Swetter said.
“Reef safe” is a marketing term with no standardized or regulatory definition in the sunscreen space, Rahman said, but the idea that some products are responsible for marine ecosystem degradation is not without merit. Studies have linked some currently approved sunscreens — namely oxybenzone and octinoxate — to coral reef bleaching and harm to the DNA of certain species.
Accordingly, starting in 2019, multiple jurisdictions, including Key West, Florida, the state of Hawaii, and the nation of Palau banned the sale and distribution of sunscreens containing those chemicals and others to protect their reef systems.
On top of this environmental hazard, oxybenzone and octinoxate are becoming less used due to concerns over endocrine disruption in marine life and even humans, Rahman said.
Against this backdrop of legitimate concern regarding chemical sunscreens, the Stanford Medicine researchers said they were not aware of evidence suggesting that bemotrizinol is harmful to the environment.
The company bringing bemotrizinol to the American market, Swiss-Dutch multinational DSM-Firmenich, has announced it will start selling its bemotrizinol formulation in August under the brand name Parsol Shield for incorporation in U.S. sunscreens, with the first products containing the filter to be available starting in September.
To demonstrate efficacy, tolerability and safety, the company reportedly spent at least $18 million over two decades to satisfy FDA regulators, including by conducting studies involving nearly 500 people “representing the diversity of the U.S. population.”
Regulators have granted DSM-Firmenich exclusive U.S. marketing rights to sell the ingredient for 18 months to help it recoup the investment. As for the price tag for bemotrizinol-containing products versus legacy sunscreens, that remains to be seen.
To that end, the Stanford Medicine experts point out that U.S. consumers can already buy high-quality and affordable bemotrizinol products from overseas through various websites, as well as scoop them up when abroad. “Whenever I travel overseas, I’ll grab sunscreens that I know we can’t get here,” Rahman said.
Of note, in addition to bemotrizinol, many foreign sunscreen products include or rely on other filters still not available domestically. Examples include Tinosorb M, Mexoryl, and Uvinul. Those extra ingredients have similar cosmetic elegance, safety, and efficacy profiles as bemotrizinol, and offer stronger ultraviolet absorption at certain wavelengths to enhance broad-spectrum filtration, Swetter said. (Bemotrizinol’s peaks are at 310 and 340 nanometers.)
The upshot is the creation of a stronger layering effect. “When you add in these other filters, you have multiple overlapping peaks of ultraviolet wavelength absorption, and that gives you longer and better protection,” Swetter said. “So, I’m hoping now that bemotrizinol has been approved, maybe we’ll see some of these other excellent filters make it to market.”
Dermatologists are thrilled because they think the cosmetic advantages of bemotrizinol will boost sunscreen use overall, delivering full-spectrum ultraviolet radiation protection to Americans for the first time.
“If you have a sunscreen that’s going to stain your clothes or leave a white cast on your skin, or if it’s going to be greasy, most people don’t want to wear it,” Rahman said. “You need to reduce the barrier to entry, and bemotrizinol does that.”
For little kids aged 2 and younger, pediatricians often previously recommended mineral sunscreens instead of chemical sunscreens containing avobenzone and oxybenzone. With bemotrizinol’s long track record of safety and effectiveness and FDA approval for children six months and older, Swetter said that encouraging sunscreen application by parents could have a transformative effect.
Risk models have shown that “if we start the regular use of sunscreen and other sun-protective measures in the first 18 years of life, we could reduce skin cancer rates by about 80% in adulthood,” she said. “Starting young is going to be really important, and the recent FDA approval of bemotrizinol is very exciting.”
Sharing the informed perspectives of those leading medical research, patient care and education at Stanford Medicine
About Stanford Medicine
Stanford Medicine is an integrated academic health system comprising the Stanford School of Medicine and adult and pediatric health care delivery systems. Together, they harness the full potential of biomedicine through collaborative research, education and clinical care for patients. For more information, please visit med.stanford.edu.
Adam Hadhazy is a freelance writer.
Skin Cancers June 23, 2025
Somehow, the idea that we need to protect our skin from the sun has blurred in recent years — largely due to online misinformation. We asked dermatologists about the science on sunscreen products.
Skin Cancers August 13, 2025
Like many among her generation, Kim Ratcliff grew up largely unaware of the dangers of sunbathing. When she got diagnosed with stage III melanoma, a team of Stanford Medicine doctors stepped in to help.
Follow Stanford Medicine:
Stanford Medicine
News
Careers
Contact
Health Care
Stanford Health Care
Stanford Children’s Health
Research
Basic Science Departments
Clinical Science Departments
Centers & Programs
Institutes
Education
A-Z Directory
Academic Programs
Faculty Development
School Contacts
©2026 Stanford School of Medicine
Privacy Policy • Terms of Use • Accessibility • Non-Discrimination
Stanford complies with all applicable civil rights laws and does not engage in illegal preferences or discrimination. 
Stanford’s Non-Discrimination Policy